Skip to main content
. 2021 May 20;13(5):762. doi: 10.3390/pharmaceutics13050762

Figure 1.

Figure 1

TCA cycle, main oncometabolites and effects on cancer biology. An altered tricarboxylic acid (TCA) cycle due to gain-of-function mutations (*) in isocitrate dehydrogenase (IDH) and loss-of-function mutations (X) in succinate dehydrogenase (SDH) and fumarate hydratase (FH), produces high levels of 2-hydroxyglutarate (2-HG), succinate and fumarate, respectively, that act as oncometabolites by pleiotropic mechanisms. PHDs: prolyl-hydroxylases; SUCNR1: succinate receptor 1; mtROS: mitochondrial reactive oxygen species; KDMs: histone lysine demethylases; TET: ten-eleven translocation proteins; HIF-1α: hypoxia-induced transcriptional factor; NHEJ: non-homologous end-joining; Cdc42: cell division control protein 42; MLK3: mixed lineage kinase 3; BCL2: B-cell lymphoma 2; EMT: epithelial mesenchymal transition.